Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan

Hsiu Ju Yen; Shih Hsiang Chen; Tsung Yen Chang; Chao Ping Yang; Dong Tsamn Lin; Iou Jih Hung; Kai Hsin Lin; Jiann Shiuh Chen; Chih Cheng Hsiao; Tai Tsung Chang; Te Kao Chang; Ching Tien Peng; Ming Tsan Lin; Tang Her Jaing; Hsi Che Liu; Shiann Tarng Jou; Meng Yao Lu; Chao Neng Cheng; Jiunn Ming Sheen; Shyh Shin Chiou; Giun Yi Hung; Kang Hsi Wu; Ting Chi Yeh; Shih Chung Wang; Rong Long Chen; Hsiu Hao Chang; Yung Li Yang; Shu Huey Chen; Shin Nan Cheng; Yu Hsiang Chang; Bow Wen Chen; Yuh Lin Hsieh; Fang Liang Huang; Wan Ling Ho; Jinn Li Wang; Chia Yau Chang; Yu Hua Chao; Pei Chin Lin; Yu Chieh Chen; Yu Mei Liao; Tung Huei Lin; Lee Yung Shih; Der Cherng Liang

doi:10.1002/pbc.26557

Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan

Hsiu Ju Yen, Shih Hsiang Chen, Tsung Yen Chang, Chao Ping Yang, Dong Tsamn Lin, Iou Jih Hung, Kai Hsin Lin, Jiann Shiuh Chen, Chih Cheng Hsiao, Tai Tsung Chang, Te Kao Chang, Ching Tien Peng, Ming Tsan Lin, Tang Her Jaing, Hsi Che Liu, Shiann Tarng Jou, Meng Yao Lu, Chao Neng Cheng, Jiunn Ming Sheen, Shyh Shin ChiouGiun Yi Hung, Kang Hsi Wu, Ting Chi Yeh, Shih Chung Wang, Rong Long Chen, Hsiu Hao Chang, Yung Li Yang, Shu Huey Chen, Shin Nan Cheng, Yu Hsiang Chang, Bow Wen Chen, Yuh Lin Hsieh, Fang Liang Huang, Wan Ling Ho, Jinn Li Wang, Chia Yau Chang, Yu Hua Chao, Pei Chin Lin, Yu Chieh Chen, Yu Mei Liao, Tung Huei Lin, Lee Yung Shih, Der Cherng Liang

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Background: In childhood acute lymphoblastic leukemia (ALL), t(1;19)(q23;p13.3) with TCF3-PBX1 fusion is one of the most frequent translocations. Historically, it has been associated with poor prognosis. Intensive treatment, however, has improved its outcome. We determined the outcome of children with this genotype treated with contemporary intensive chemotherapy in Taiwan. Procedure: In Taiwan Pediatric Oncology Group 2002 ALL studies, genotypes were determined by cytogenetic analysis and/or reverse transcriptase polymerase chain reaction assay. Based on presenting features, immunophenotype and genotype, patients were assigned to one of the three risk groups: standard risk (SR), high risk (HR), or very high risk (VHR). The patients with t(1;19)/TCF3-PBX1 were treated in the HR arm receiving more intensive chemotherapy. The outcomes of patients with t(1;19)/TCF3-PBX1 were compared to that of patients with other subtypes of B-precursor ALL (B-ALL). Results: Of the 1,129 patients with B-ALL, 64 (5.7%) had t(1;19)/TCF3-PBX1; 51 of whom were treated in the HR arm, but 11 were treated in the VHR and 2 in the SR arm because of physician's preference. As a group, 64 patients with t(1;19)/TCF3-PBX1 had similar 5-year event-free survival (83.3 ± 4.8%) as those with TEL-AML1 (85.2 ± 3.4%, P = 0.984) or those with hyperdiploidy >50 (84.0 ± 3.1%, P = 0.748). The cumulative risk of any (isolated plus combined) central nervous system relapse among patients with t(1;19)/TCF3-PBX1 (8.7 ± 3.8%) tended to be higher than that of patients with TEL-AML1 (5.8 ± 2.3%, P = 0.749) or those with hyperdiploidy (4.1 ± 1.8%, P = 0.135), albeit the differences did not reach statistical significance. Conclusions: With contemporary intensive chemotherapy, children with t(1;19)/TCF3-PBX1 fared as well as those with favorable genotypes (TEL-AML1 or hyperdiploidy).

Original language	English
Article number	e26557
Journal	Pediatric Blood and Cancer
Volume	64
Issue number	10
DOIs	https://doi.org/10.1002/pbc.26557
Publication status	Published - 2017 Oct

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.26557

Cite this

Yen, H. J., Chen, S. H., Chang, T. Y., Yang, C. P., Lin, D. T., Hung, I. J., Lin, K. H., Chen, J. S., Hsiao, C. C., Chang, T. T., Chang, T. K., Peng, C. T., Lin, M. T., Jaing, T. H., Liu, H. C., Jou, S. T., Lu, M. Y., Cheng, C. N., Sheen, J. M., ... Liang, D. C. (2017). Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan. Pediatric Blood and Cancer, 64(10), Article e26557. https://doi.org/10.1002/pbc.26557

@article{62b69dd61cfb4f4c95237a6e99b5318b,

title = "Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan",

abstract = "Background: In childhood acute lymphoblastic leukemia (ALL), t(1;19)(q23;p13.3) with TCF3-PBX1 fusion is one of the most frequent translocations. Historically, it has been associated with poor prognosis. Intensive treatment, however, has improved its outcome. We determined the outcome of children with this genotype treated with contemporary intensive chemotherapy in Taiwan. Procedure: In Taiwan Pediatric Oncology Group 2002 ALL studies, genotypes were determined by cytogenetic analysis and/or reverse transcriptase polymerase chain reaction assay. Based on presenting features, immunophenotype and genotype, patients were assigned to one of the three risk groups: standard risk (SR), high risk (HR), or very high risk (VHR). The patients with t(1;19)/TCF3-PBX1 were treated in the HR arm receiving more intensive chemotherapy. The outcomes of patients with t(1;19)/TCF3-PBX1 were compared to that of patients with other subtypes of B-precursor ALL (B-ALL). Results: Of the 1,129 patients with B-ALL, 64 (5.7%) had t(1;19)/TCF3-PBX1; 51 of whom were treated in the HR arm, but 11 were treated in the VHR and 2 in the SR arm because of physician's preference. As a group, 64 patients with t(1;19)/TCF3-PBX1 had similar 5-year event-free survival (83.3 ± 4.8%) as those with TEL-AML1 (85.2 ± 3.4%, P = 0.984) or those with hyperdiploidy >50 (84.0 ± 3.1%, P = 0.748). The cumulative risk of any (isolated plus combined) central nervous system relapse among patients with t(1;19)/TCF3-PBX1 (8.7 ± 3.8%) tended to be higher than that of patients with TEL-AML1 (5.8 ± 2.3%, P = 0.749) or those with hyperdiploidy (4.1 ± 1.8%, P = 0.135), albeit the differences did not reach statistical significance. Conclusions: With contemporary intensive chemotherapy, children with t(1;19)/TCF3-PBX1 fared as well as those with favorable genotypes (TEL-AML1 or hyperdiploidy).",

author = "Yen, {Hsiu Ju} and Chen, {Shih Hsiang} and Chang, {Tsung Yen} and Yang, {Chao Ping} and Lin, {Dong Tsamn} and Hung, {Iou Jih} and Lin, {Kai Hsin} and Chen, {Jiann Shiuh} and Hsiao, {Chih Cheng} and Chang, {Tai Tsung} and Chang, {Te Kao} and Peng, {Ching Tien} and Lin, {Ming Tsan} and Jaing, {Tang Her} and Liu, {Hsi Che} and Jou, {Shiann Tarng} and Lu, {Meng Yao} and Cheng, {Chao Neng} and Sheen, {Jiunn Ming} and Chiou, {Shyh Shin} and Hung, {Giun Yi} and Wu, {Kang Hsi} and Yeh, {Ting Chi} and Wang, {Shih Chung} and Chen, {Rong Long} and Chang, {Hsiu Hao} and Yang, {Yung Li} and Chen, {Shu Huey} and Cheng, {Shin Nan} and Chang, {Yu Hsiang} and Chen, {Bow Wen} and Hsieh, {Yuh Lin} and Huang, {Fang Liang} and Ho, {Wan Ling} and Wang, {Jinn Li} and Chang, {Chia Yau} and Chao, {Yu Hua} and Lin, {Pei Chin} and Chen, {Yu Chieh} and Liao, {Yu Mei} and Lin, {Tung Huei} and Shih, {Lee Yung} and Liang, {Der Cherng}",

note = "Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2017",

month = oct,

doi = "10.1002/pbc.26557",

language = "English",

volume = "64",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "10",

}

Yen, HJ, Chen, SH, Chang, TY, Yang, CP, Lin, DT, Hung, IJ, Lin, KH, Chen, JS, Hsiao, CC, Chang, TT, Chang, TK, Peng, CT, Lin, MT, Jaing, TH, Liu, HC, Jou, ST, Lu, MY, Cheng, CN, Sheen, JM, Chiou, SS, Hung, GY, Wu, KH, Yeh, TC, Wang, SC, Chen, RL, Chang, HH, Yang, YL, Chen, SH, Cheng, SN, Chang, YH, Chen, BW, Hsieh, YL, Huang, FL, Ho, WL, Wang, JL, Chang, CY, Chao, YH, Lin, PC, Chen, YC, Liao, YM, Lin, TH, Shih, LY & Liang, DC 2017, 'Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan', Pediatric Blood and Cancer, vol. 64, no. 10, e26557. https://doi.org/10.1002/pbc.26557

TY - JOUR

T1 - Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan

AU - Yen, Hsiu Ju

AU - Chen, Shih Hsiang

AU - Chang, Tsung Yen

AU - Yang, Chao Ping

AU - Lin, Dong Tsamn

AU - Hung, Iou Jih

AU - Lin, Kai Hsin

AU - Chen, Jiann Shiuh

AU - Hsiao, Chih Cheng

AU - Chang, Tai Tsung

AU - Chang, Te Kao

AU - Peng, Ching Tien

AU - Lin, Ming Tsan

AU - Jaing, Tang Her

AU - Liu, Hsi Che

AU - Jou, Shiann Tarng

AU - Lu, Meng Yao

AU - Cheng, Chao Neng

AU - Sheen, Jiunn Ming

AU - Chiou, Shyh Shin

AU - Hung, Giun Yi

AU - Wu, Kang Hsi

AU - Yeh, Ting Chi

AU - Wang, Shih Chung

AU - Chen, Rong Long

AU - Chang, Hsiu Hao

AU - Yang, Yung Li

AU - Chen, Shu Huey

AU - Cheng, Shin Nan

AU - Chang, Yu Hsiang

AU - Chen, Bow Wen

AU - Hsieh, Yuh Lin

AU - Huang, Fang Liang

AU - Ho, Wan Ling

AU - Wang, Jinn Li

AU - Chang, Chia Yau

AU - Chao, Yu Hua

AU - Lin, Pei Chin

AU - Chen, Yu Chieh

AU - Liao, Yu Mei

AU - Lin, Tung Huei

AU - Shih, Lee Yung

AU - Liang, Der Cherng

PY - 2017/10

Y1 - 2017/10

N2 - Background: In childhood acute lymphoblastic leukemia (ALL), t(1;19)(q23;p13.3) with TCF3-PBX1 fusion is one of the most frequent translocations. Historically, it has been associated with poor prognosis. Intensive treatment, however, has improved its outcome. We determined the outcome of children with this genotype treated with contemporary intensive chemotherapy in Taiwan. Procedure: In Taiwan Pediatric Oncology Group 2002 ALL studies, genotypes were determined by cytogenetic analysis and/or reverse transcriptase polymerase chain reaction assay. Based on presenting features, immunophenotype and genotype, patients were assigned to one of the three risk groups: standard risk (SR), high risk (HR), or very high risk (VHR). The patients with t(1;19)/TCF3-PBX1 were treated in the HR arm receiving more intensive chemotherapy. The outcomes of patients with t(1;19)/TCF3-PBX1 were compared to that of patients with other subtypes of B-precursor ALL (B-ALL). Results: Of the 1,129 patients with B-ALL, 64 (5.7%) had t(1;19)/TCF3-PBX1; 51 of whom were treated in the HR arm, but 11 were treated in the VHR and 2 in the SR arm because of physician's preference. As a group, 64 patients with t(1;19)/TCF3-PBX1 had similar 5-year event-free survival (83.3 ± 4.8%) as those with TEL-AML1 (85.2 ± 3.4%, P = 0.984) or those with hyperdiploidy >50 (84.0 ± 3.1%, P = 0.748). The cumulative risk of any (isolated plus combined) central nervous system relapse among patients with t(1;19)/TCF3-PBX1 (8.7 ± 3.8%) tended to be higher than that of patients with TEL-AML1 (5.8 ± 2.3%, P = 0.749) or those with hyperdiploidy (4.1 ± 1.8%, P = 0.135), albeit the differences did not reach statistical significance. Conclusions: With contemporary intensive chemotherapy, children with t(1;19)/TCF3-PBX1 fared as well as those with favorable genotypes (TEL-AML1 or hyperdiploidy).

AB - Background: In childhood acute lymphoblastic leukemia (ALL), t(1;19)(q23;p13.3) with TCF3-PBX1 fusion is one of the most frequent translocations. Historically, it has been associated with poor prognosis. Intensive treatment, however, has improved its outcome. We determined the outcome of children with this genotype treated with contemporary intensive chemotherapy in Taiwan. Procedure: In Taiwan Pediatric Oncology Group 2002 ALL studies, genotypes were determined by cytogenetic analysis and/or reverse transcriptase polymerase chain reaction assay. Based on presenting features, immunophenotype and genotype, patients were assigned to one of the three risk groups: standard risk (SR), high risk (HR), or very high risk (VHR). The patients with t(1;19)/TCF3-PBX1 were treated in the HR arm receiving more intensive chemotherapy. The outcomes of patients with t(1;19)/TCF3-PBX1 were compared to that of patients with other subtypes of B-precursor ALL (B-ALL). Results: Of the 1,129 patients with B-ALL, 64 (5.7%) had t(1;19)/TCF3-PBX1; 51 of whom were treated in the HR arm, but 11 were treated in the VHR and 2 in the SR arm because of physician's preference. As a group, 64 patients with t(1;19)/TCF3-PBX1 had similar 5-year event-free survival (83.3 ± 4.8%) as those with TEL-AML1 (85.2 ± 3.4%, P = 0.984) or those with hyperdiploidy >50 (84.0 ± 3.1%, P = 0.748). The cumulative risk of any (isolated plus combined) central nervous system relapse among patients with t(1;19)/TCF3-PBX1 (8.7 ± 3.8%) tended to be higher than that of patients with TEL-AML1 (5.8 ± 2.3%, P = 0.749) or those with hyperdiploidy (4.1 ± 1.8%, P = 0.135), albeit the differences did not reach statistical significance. Conclusions: With contemporary intensive chemotherapy, children with t(1;19)/TCF3-PBX1 fared as well as those with favorable genotypes (TEL-AML1 or hyperdiploidy).

UR - http://www.scopus.com/inward/record.url?scp=85018871703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018871703&partnerID=8YFLogxK

U2 - 10.1002/pbc.26557

DO - 10.1002/pbc.26557

M3 - Article

C2 - 28436581

AN - SCOPUS:85018871703

SN - 1545-5009

VL - 64

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 10

M1 - e26557

ER -

Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this